Alkermes plc (ALKS)
USD 28.87
(-3.98%)
USD 28.87
(-3.98%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 355.75 Million USD | 324.78% |
| 2022 | -158.26 Million USD | -228.57% |
| 2021 | -48.16 Million USD | 56.55% |
| 2020 | -110.86 Million USD | 43.62% |
| 2019 | -196.62 Million USD | -41.14% |
| 2018 | -139.31 Million USD | 11.8% |
| 2017 | -157.94 Million USD | 24.23% |
| 2016 | -208.44 Million USD | 8.24% |
| 2015 | -227.16 Million USD | -655.67% |
| 2014 | -30.06 Million USD | -220.33% |
| 2013 | 24.98 Million USD | 121.98% |
| 2012 | -113.67 Million USD | -149.62% |
| 2011 | -45.54 Million USD | -14.92% |
| 2010 | -39.62 Million USD | -130.36% |
| 2009 | 130.5 Million USD | -21.84% |
| 2008 | 166.97 Million USD | 1667.91% |
| 2007 | 9.44 Million USD | 147.38% |
| 2006 | 3.81 Million USD | 105.17% |
| 2005 | -73.91 Million USD | 27.81% |
| 2004 | -102.38 Million USD | 4.22% |
| 2003 | -106.89 Million USD | -74.23% |
| 2002 | -61.35 Million USD | -263.71% |
| 2001 | -16.86 Million USD | 75.21% |
| 2000 | -68.04 Million USD | -65.74% |
| 1999 | -41.05 Million USD | -320.18% |
| 1998 | -9.77 Million USD | 48.02% |
| 1997 | -18.79 Million USD | -37.21% |
| 1996 | -13.7 Million USD | -15.13% |
| 1995 | -11.9 Million USD | 31.21% |
| 1994 | -17.3 Million USD | 56.86% |
| 1993 | -40.1 Million USD | -395.06% |
| 1992 | -8.1 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 36.82 Million USD | -67.34% |
| 2024 Q3 | 92.38 Million USD | 1.12% |
| 2024 Q2 | 91.35 Million USD | 148.07% |
| 2023 Q4 | 112.77 Million USD | 136.15% |
| 2023 Q1 | -41.84 Million USD | -48.1% |
| 2023 Q2 | 237.06 Million USD | 666.53% |
| 2023 FY | 355.75 Million USD | 324.78% |
| 2023 Q3 | 47.75 Million USD | -79.85% |
| 2022 FY | -158.26 Million USD | -228.57% |
| 2022 Q1 | -35.9 Million USD | -4212.6% |
| 2022 Q2 | -30.13 Million USD | 16.06% |
| 2022 Q3 | -63.97 Million USD | -112.28% |
| 2022 Q4 | -28.25 Million USD | 55.84% |
| 2021 Q1 | -22.41 Million USD | 47.43% |
| 2021 FY | -48.16 Million USD | 56.55% |
| 2021 Q2 | 2.36 Million USD | 110.55% |
| 2021 Q3 | -28.98 Million USD | -1326.23% |
| 2021 Q4 | 873 Thousand USD | 103.01% |
| 2020 Q1 | -38.65 Million USD | -621.96% |
| 2020 Q2 | -29.43 Million USD | 23.86% |
| 2020 Q3 | -134 Thousand USD | 99.54% |
| 2020 Q4 | -42.64 Million USD | -31722.39% |
| 2020 FY | -110.86 Million USD | 43.62% |
| 2019 Q3 | -52.87 Million USD | -25.93% |
| 2019 Q2 | -41.99 Million USD | 56.44% |
| 2019 FY | -196.62 Million USD | -41.14% |
| 2019 Q1 | -96.39 Million USD | -892.46% |
| 2019 Q4 | -5.35 Million USD | 89.87% |
| 2018 Q3 | -34.44 Million USD | -5.5% |
| 2018 Q1 | -62.5 Million USD | -538.52% |
| 2018 FY | -139.31 Million USD | 11.8% |
| 2018 Q4 | -9.71 Million USD | 71.8% |
| 2018 Q2 | -32.64 Million USD | 47.77% |
| 2017 Q4 | -9.78 Million USD | 73.02% |
| 2017 FY | -157.94 Million USD | 24.23% |
| 2017 Q1 | -68.88 Million USD | -225.82% |
| 2017 Q2 | -42.99 Million USD | 37.57% |
| 2017 Q3 | -36.27 Million USD | 15.64% |
| 2016 Q4 | -21.14 Million USD | 66.28% |
| 2016 Q3 | -62.68 Million USD | -32.83% |
| 2016 FY | -208.44 Million USD | 8.24% |
| 2016 Q2 | -47.19 Million USD | 39.05% |
| 2016 Q1 | -77.42 Million USD | -11.59% |
| 2015 Q1 | -30.65 Million USD | -200.47% |
| 2015 FY | -227.16 Million USD | -655.67% |
| 2015 Q4 | -69.38 Million USD | 14.36% |
| 2015 Q3 | -81.01 Million USD | -75.7% |
| 2015 Q2 | -46.1 Million USD | -50.4% |
| 2014 FY | -30.06 Million USD | -220.33% |
| 2014 Q1 | -24.35 Million USD | -234.71% |
| 2014 Q2 | 3.73 Million USD | 115.34% |
| 2014 Q4 | 30.51 Million USD | 176.37% |
| 2014 Q3 | -39.95 Million USD | -1169.77% |
| 2013 Q3 | -7.76 Million USD | -205.84% |
| 2013 Q1 | 2.99 Million USD | -81.55% |
| 2013 FY | 24.98 Million USD | 121.98% |
| 2013 Q4 | 18.07 Million USD | 332.92% |
| 2013 Q2 | 7.33 Million USD | 144.55% |
| 2012 FY | -113.67 Million USD | -149.62% |
| 2012 Q4 | 16.25 Million USD | 197.31% |
| 2012 Q3 | -16.7 Million USD | -174.48% |
| 2012 Q2 | 22.43 Million USD | 135.41% |
| 2012 Q1 | -63.35 Million USD | -327.28% |
| 2011 Q3 | -22.25 Million USD | -68.11% |
| 2011 Q4 | -14.82 Million USD | 33.37% |
| 2011 FY | -45.54 Million USD | -14.92% |
| 2011 Q2 | -13.23 Million USD | -1.19% |
| 2011 Q1 | -13.08 Million USD | -14.93% |
| 2010 FY | -39.62 Million USD | -130.36% |
| 2010 Q1 | -13.93 Million USD | -104.42% |
| 2010 Q4 | -11.38 Million USD | -48.49% |
| 2010 Q3 | -7.66 Million USD | 42.83% |
| 2010 Q2 | -13.4 Million USD | 3.77% |
| 2009 Q2 | -10.16 Million USD | 25.23% |
| 2009 Q1 | -13.59 Million USD | -112.06% |
| 2009 FY | 130.5 Million USD | -21.84% |
| 2009 Q4 | -6.81 Million USD | 21.72% |
| 2009 Q3 | -8.7 Million USD | 14.32% |
| 2008 Q1 | -18.34 Million USD | -110.86% |
| 2008 Q3 | 1.69 Million USD | -94.28% |
| 2008 Q4 | 112.71 Million USD | 6538.1% |
| 2008 FY | 166.97 Million USD | 1667.91% |
| 2008 Q2 | 29.68 Million USD | 261.81% |
| 2007 Q4 | 168.88 Million USD | 2093.83% |
| 2007 Q2 | 8.74 Million USD | 149.84% |
| 2007 Q1 | 3.5 Million USD | 19.37% |
| 2007 FY | 9.44 Million USD | 147.38% |
| 2007 Q3 | 7.69 Million USD | -11.99% |
| 2006 Q4 | 2.93 Million USD | -21.28% |
| 2006 Q3 | 3.72 Million USD | 621.12% |
| 2006 Q2 | -715 Thousand USD | -116.26% |
| 2006 Q1 | 4.39 Million USD | 212.44% |
| 2006 FY | 3.81 Million USD | 105.17% |
| 2005 FY | -73.91 Million USD | 27.81% |
| 2005 Q4 | 1.4 Million USD | -88.03% |
| 2005 Q1 | -14.5 Million USD | -61.17% |
| 2005 Q2 | -13.73 Million USD | 5.29% |
| 2005 Q3 | 11.75 Million USD | 185.55% |
| 2004 Q4 | -8.99 Million USD | 36.91% |
| 2004 Q1 | -24.72 Million USD | -18.53% |
| 2004 FY | -102.38 Million USD | 4.22% |
| 2004 Q2 | -36.14 Million USD | -46.17% |
| 2004 Q3 | -14.26 Million USD | 60.54% |
| 2003 Q1 | -35.04 Million USD | -184.96% |
| 2003 Q3 | -26.21 Million USD | 14.24% |
| 2003 Q4 | -20.86 Million USD | 20.43% |
| 2003 FY | -106.89 Million USD | -74.23% |
| 2003 Q2 | -30.57 Million USD | 12.77% |
| 2002 FY | -61.35 Million USD | -263.71% |
| 2002 Q4 | 41.24 Million USD | 160.8% |
| 2002 Q1 | -22.49 Million USD | -25.69% |
| 2002 Q2 | -45.25 Million USD | -101.13% |
| 2002 Q3 | -67.84 Million USD | -49.94% |
| 2001 FY | -16.86 Million USD | 75.21% |
| 2001 Q3 | -12.61 Million USD | -51.19% |
| 2001 Q1 | -10.99 Million USD | -49.38% |
| 2001 Q2 | -8.34 Million USD | 24.09% |
| 2001 Q4 | -17.9 Million USD | -41.92% |
| 2000 Q2 | 7.89 Million USD | 128.08% |
| 2000 FY | -68.04 Million USD | -65.74% |
| 2000 Q4 | -7.35 Million USD | 11.2% |
| 2000 Q1 | -28.12 Million USD | -63.5% |
| 2000 Q3 | -8.28 Million USD | -204.93% |
| 1999 FY | -41.05 Million USD | -320.18% |
| 1999 Q3 | -14.42 Million USD | -74.07% |
| 1999 Q2 | -8.28 Million USD | 73.4% |
| 1999 Q1 | -31.16 Million USD | -1321.16% |
| 1999 Q4 | -17.2 Million USD | -19.23% |
| 1998 Q1 | -1.77 Million USD | 41.0% |
| 1998 FY | -9.77 Million USD | 48.02% |
| 1998 Q4 | -2.19 Million USD | 16.5% |
| 1998 Q3 | -2.62 Million USD | 48.27% |
| 1998 Q2 | -5.07 Million USD | -185.99% |
| 1997 Q1 | -4.82 Million USD | -13.95% |
| 1997 FY | -18.79 Million USD | -37.21% |
| 1997 Q4 | -3 Million USD | -213.56% |
| 1997 Q3 | -959.55 Thousand USD | 76.18% |
| 1997 Q2 | -4.02 Million USD | 16.57% |
| 1996 Q3 | -4.78 Million USD | 3.13% |
| 1996 Q4 | -4.23 Million USD | 11.54% |
| 1996 Q2 | -4.94 Million USD | 10.11% |
| 1996 Q1 | -5.5 Million USD | -96.43% |
| 1996 FY | -13.7 Million USD | -15.13% |
| 1995 Q2 | -2.5 Million USD | 21.88% |
| 1995 Q1 | -3.2 Million USD | -68.42% |
| 1995 Q4 | -2.8 Million USD | 6.67% |
| 1995 FY | -11.9 Million USD | 31.21% |
| 1995 Q3 | -3 Million USD | -20.0% |
| 1994 FY | -17.3 Million USD | 56.86% |
| 1994 Q4 | -1.9 Million USD | 38.71% |
| 1994 Q3 | -3.1 Million USD | 16.22% |
| 1994 Q2 | -3.7 Million USD | 5.13% |
| 1994 Q1 | -3.9 Million USD | 22.0% |
| 1993 Q4 | -5 Million USD | -35.14% |
| 1993 Q1 | -35 Million USD | -1566.67% |
| 1993 FY | -40.1 Million USD | -395.06% |
| 1993 Q2 | -4.7 Million USD | 86.57% |
| 1993 Q3 | -3.7 Million USD | 21.28% |
| 1992 Q3 | -2.1 Million USD | -133.33% |
| 1992 FY | -8.1 Million USD | 0.0% |
| 1992 Q2 | -900 Thousand USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 Q4 | -2.1 Million USD | 0.0% |
| 1991 Q4 | - USD | 100.0% |
| 1991 Q2 | -1.9 Million USD | 0.0% |
| 1991 Q3 | -1.6 Million USD | 15.79% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 343.007% |
| Agenus Inc. | -245.76 Million USD | 244.757% |
| Aptorum Group Limited | -2.82 Million USD | 12694.742% |
| Ardelyx, Inc. | -66.06 Million USD | 638.479% |
| Dyadic International, Inc. | -6.79 Million USD | 5335.215% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 38108.226% |
| Lantern Pharma Inc. | -15.96 Million USD | 2328.84% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 1969.563% |
| Novavax, Inc. | -545.06 Million USD | 165.269% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 710.291% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 582.121% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 2018.231% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 3662.558% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 703.155% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 195.216% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 1561.657% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 1052.75% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 316.168% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 585.033% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 1853.275% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 671.451% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 1195.142% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 368.51% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 180.809% |
| AlloVir, Inc. | -190.41 Million USD | 286.83% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 273.308% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 1350.376% |
| Bicycle Therapeutics plc | -180.66 Million USD | 296.916% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 298.688% |
| ChromaDex Corporation | -4.93 Million USD | 7304.475% |
| Chimerix, Inc. | -82.09 Million USD | 533.348% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 897.602% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 448.542% |
| CRISPR Therapeutics AG | -153.61 Million USD | 331.598% |
| Precision BioSciences, Inc. | -61.31 Million USD | 680.174% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 321.066% |
| Fortress Biotech, Inc. | -60.63 Million USD | 686.7% |
| Fortress Biotech, Inc. | -60.63 Million USD | 686.7% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 536.084% |
| ImmuCell Corporation | -5.77 Million USD | 6260.723% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 414.938% |
| Immix Biopharma, Inc. | -15.42 Million USD | 2406.21% |
| Incyte Corporation | 597.59 Million USD | 40.469% |
| Innoviva, Inc. | 179.72 Million USD | -97.948% |
| IO Biotech, Inc. | -86.08 Million USD | 513.272% |
| Jaguar Health, Inc. | -41.3 Million USD | 961.397% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 332.533% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -582.128% |
| ContextLogic Inc. | -317 Million USD | 212.226% |
| MiMedx Group, Inc. | 67.43 Million USD | -427.524% |
| MEI Pharma, Inc. | 17.77 Million USD | -1901.108% |
| NextCure, Inc. | -62.72 Million USD | 667.187% |
| Onconetix, Inc. | -37.4 Million USD | 1050.975% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 1001.13% |
| Opthea Limited | -220.24 Million USD | 261.53% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 795.394% |
| Vaxcyte, Inc. | -402.26 Million USD | 188.438% |
| PDS Biotechnology Corporation | -42.94 Million USD | 928.455% |
| Precigen, Inc. | -95.9 Million USD | 470.951% |
| Pharming Group N.V. | -10.54 Million USD | 3472.744% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 276.474% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 1549.525% |
| PureTech Health plc | -65.69 Million USD | 641.512% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 1517.867% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 267.636% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 1561.657% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 237.981% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 1406.105% |
| Acelyrin, Inc. | -381.64 Million USD | 193.218% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 2836469.232% |
| Summit Therapeutics Inc. | -614.92 Million USD | 157.853% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 1143.245% |
| Senti Biosciences, Inc. | -92.91 Million USD | 482.868% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 439.79% |
| Elevation Oncology, Inc. | -45.7 Million USD | 878.394% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 1112.399% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 2821.548% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 5421.72% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 1311.624% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 4284.884% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 718.568% |
| Seer, Inc. | -86.27 Million USD | 512.343% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 631.02% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 640.952% |
| ESSA Pharma Inc. | -26.58 Million USD | 1438.321% |
| GlycoMimetics, Inc. | -36.89 Million USD | 1064.126% |
| GT Biopharma, Inc. | -7.59 Million USD | 4782.862% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 247.396% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 785.136% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -398.189% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 753.701% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 824.261% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 3676.257% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 162.104% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 10015.19% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 796.77% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 244.855% |
| Aptose Biosciences Inc. | -51.2 Million USD | 794.743% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 461.917% |
| Soligenix, Inc. | -6.14 Million USD | 5893.399% |
| Century Therapeutics, Inc. | -136.67 Million USD | 360.298% |
| Kura Oncology, Inc. | -152.63 Million USD | 333.083% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 498.75% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 3475.944% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -62813.506% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 62623.199% |
| Autolus Therapeutics plc | -208.38 Million USD | 270.723% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 594.808% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 602.517% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 1741.854% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 257.939% |
| GRI Bio, Inc. | -13.03 Million USD | 2828.826% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 8704.433% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 386.707% |
| IGM Biosciences, Inc. | -246.41 Million USD | 244.373% |
| INmune Bio, Inc. | -30 Million USD | 1285.541% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 421.78% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 943.15% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 2328.822% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 2352.342% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 696.058% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 451.653% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 228.839% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 249.546% |
| Verastem, Inc. | -87.36 Million USD | 507.198% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 756.524% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 320.507% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 404.957% |
| Histogen Inc. | -10.62 Million USD | 3449.562% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 2590.117% |
| Surrozen, Inc. | -43.04 Million USD | 926.535% |
| Organovo Holdings, Inc. | -14.67 Million USD | 2524.899% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 7093.414% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 779.717% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 1508.214% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 1420.651% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 4356.95% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 335.468% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 827.132% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 1296.828% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 3514.927% |
| Apollomics, Inc. | -172.6 Million USD | 306.115% |
| Amarin Corporation plc | -59.11 Million USD | 701.835% |
| Mesoblast Limited | -87.95 Million USD | 504.472% |
| Turnstone Biologics Corp. | -55.2 Million USD | 744.487% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 342.074% |
| Synaptogenix, Inc. | -6.03 Million USD | 5991.476% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 2294.947% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 555.982% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 7524.805% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 4334.095% |
| Exelixis, Inc. | 207.76 Million USD | -71.23% |
| Better Therapeutics, Inc. | -39.76 Million USD | 994.761% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 347.143% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 167.298% |
| NLS Pharmaceutics AG | -12.17 Million USD | 3022.742% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 4664.094% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 1256.971% |
| Gritstone bio, Inc. | -138.49 Million USD | 356.883% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 651.861% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 8994.036% |
| Avid Bioservices, Inc. | -140.75 Million USD | 352.753% |
| Insmed Incorporated | -749.56 Million USD | 147.462% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 2442.123% |
| MediWound Ltd. | -6.71 Million USD | 5397.156% |
| OmniAb, Inc. | -50.61 Million USD | 802.813% |
| Alector, Inc. | -130.39 Million USD | 372.839% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 412.825% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 786.167% |
| Zai Lab Limited | -334.62 Million USD | 206.317% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 209.806% |
| Aura Biosciences, Inc. | -76.4 Million USD | 565.602% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 251.623% |
| Immunic, Inc. | -93.61 Million USD | 480.034% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 361.792% |
| Veracyte, Inc. | -74.4 Million USD | 578.142% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 4734.938% |
| FibroGen, Inc. | -284.23 Million USD | 225.164% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 1456.195% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 5180.871% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 1989.039% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 14.241% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 1677.287% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -622.041% |
| TG Therapeutics, Inc. | 12.67 Million USD | -2707.426% |
| Galecto, Inc. | -38.34 Million USD | 1027.683% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 1985.704% |
| Fortrea Holdings Inc. | -3.4 Million USD | 10563.441% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 380.911% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 2143.289% |
| XBiotech Inc. | -24.55 Million USD | 1548.699% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 651.861% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 667.577% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 461.446% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 1760.321% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 744.569% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 158.644% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 621.217% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 624958.608% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 257.04% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 1697.65% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 261.921% |
| NexImmune, Inc. | -32.34 Million USD | 1199.903% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 6829.443% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 2632.818% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 91.002% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 1568.796% |
| Scopus BioPharma Inc. | -11.6 Million USD | 3164.275% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 404.592% |
| Ainos, Inc. | -13.77 Million USD | 2683.463% |
| Pluri Inc. | -20.88 Million USD | 1803.164% |
| Prothena Corporation plc | -147.02 Million USD | 341.965% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 412.421% |
| Celularity Inc. | -196.29 Million USD | 281.236% |
| Rallybio Corporation | -74.56 Million USD | 577.116% |
| Cue Biopharma, Inc. | -50.73 Million USD | 801.234% |
| MeiraGTx Holdings plc | -84.02 Million USD | 523.384% |
| Omeros Corporation | -117.81 Million USD | 401.968% |
| Humacyte, Inc. | -110.77 Million USD | 421.15% |
| Immunocore Holdings plc | -55.28 Million USD | 743.473% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 2078.186% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 1651.424% |
| Blueprint Medicines Corporation | -506.98 Million USD | 170.171% |
| CalciMedica, Inc. | -34.35 Million USD | 1135.472% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 625.685% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 351.587% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 314.584% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 225.596% |
| Pulmatrix, Inc. | -14.12 Million USD | 2619.347% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 1110.817% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 530.5% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 173.932% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 439.233% |
| Cytokinetics, Incorporated | -526.24 Million USD | 167.603% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 1086.433% |
| Nutriband Inc. | -5.48 Million USD | 6585.627% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 980.151% |
| Vor Biopharma Inc. | -117.86 Million USD | 401.839% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 91.82% |
| Evogene Ltd. | -23.87 Million USD | 1589.832% |
| ProKidney Corp. | -35.46 Million USD | 1103.037% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 397.051% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 4634.599% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 155.31% |
| CorMedix Inc. | -46.33 Million USD | 867.723% |
| BioLineRx Ltd. | -60.61 Million USD | 686.922% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 449.659% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 966.305% |
| Atai Life Sciences N.V. | -40.22 Million USD | 984.44% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 541.111% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 571.07% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 221.755% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 1376.213% |
| MediciNova, Inc. | -8.57 Million USD | 4250.456% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 388.583% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 4346.915% |
| GeoVax Labs, Inc. | -25.96 Million USD | 1470.048% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 248.704% |
| Biomea Fusion, Inc. | -117.25 Million USD | 403.405% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 156.775% |
| Mereo BioPharma Group plc | -29.46 Million USD | 1307.347% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 332.275% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 269.926% |
| Absci Corporation | -110.56 Million USD | 421.76% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 1279.957% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 452.804% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 250.785% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -2425.966% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 284.366% |
| Allakos Inc. | -185.7 Million USD | 291.575% |
| Imunon, Inc. | -19.51 Million USD | 1922.995% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 465.498% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -235.177% |
| BioAtla, Inc. | -123.46 Million USD | 388.151% |
| NLS Pharmaceutics AG | -12.17 Million USD | 3022.742% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 2312.694% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 208.706% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 1062.833% |
| XOMA Corporation | -40.83 Million USD | 971.291% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 449.226% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 400.184% |
| aTyr Pharma, Inc. | -50.38 Million USD | 806.021% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 505.749% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 334.422% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 249.645% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 1113.004% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 4496.436% |
| Akari Therapeutics, Plc | -10 Million USD | 3654.726% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 528517.378% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -26.337% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 5437.77% |
| UroGen Pharma Ltd. | -102.24 Million USD | 447.949% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 433.128% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 4674.368% |
| Orgenesis Inc. | -55.36 Million USD | 742.613% |
| Entera Bio Ltd. | -8.88 Million USD | 4102.216% |
| GH Research PLC | -35.58 Million USD | 1099.682% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 1807.087% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 559.706% |
| Xencor, Inc. | -126.08 Million USD | 382.152% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 9547.296% |
| Replimune Group, Inc. | -215.79 Million USD | 264.86% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 1772.849% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -14079.235% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 5437.77% |
| Portage Biotech Inc. | -75.33 Million USD | 572.208% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 4346.915% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 468.069% |
| OncoCyte Corporation | -27.78 Million USD | 1380.577% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 2751.497% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 3298.816% |
| Purple Biotech Ltd. | -19.88 Million USD | 1889.522% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 5168.486% |
| scPharmaceuticals Inc. | -54.81 Million USD | 749.073% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 2132.184% |
| HilleVax, Inc. | -123.56 Million USD | 387.908% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 3619.907% |
| Tharimmune, Inc. | -9.31 Million USD | 3917.506% |
| Genprex, Inc. | -30.86 Million USD | 1252.792% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 250.792% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 1282.153% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 20063.917% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 6817.447% |
| OKYO Pharma Limited | -16.82 Thousand USD | 2114496.872% |
| Savara Inc. | -54.69 Million USD | 750.402% |
| Curis, Inc. | -47.41 Million USD | 850.336% |
| Daré Bioscience, Inc. | -30.16 Million USD | 1279.511% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 2403.367% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 6488.167% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 1293.215% |
| BeiGene, Ltd. | -881.7 Million USD | 140.349% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 1770.691% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 181.527% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 550.582% |
| Erasca, Inc. | -125.04 Million USD | 384.51% |
| bluebird bio, Inc. | -211.91 Million USD | 267.879% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 7214.433% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -112.209% |
| DBV Technologies S.A. | -72.72 Million USD | 589.174% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 7214.433% |
| Moderna, Inc. | -4.71 Billion USD | 107.547% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 985.915% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 6347.928% |
| Molecular Templates, Inc. | -8.12 Million USD | 4479.087% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 689.119% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 419.354% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 362.838% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 842.413% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 351.545% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 284.895% |
| MacroGenics, Inc. | -9.05 Million USD | 4027.545% |
| RenovoRx, Inc. | -10.23 Million USD | 3576.906% |
| Adicet Bio, Inc. | -142.65 Million USD | 349.378% |
| Prime Medicine, Inc. | -198.13 Million USD | 279.555% |
| Aditxt, Inc. | -32.38 Million USD | 1198.665% |
| Adagene Inc. | -18.94 Million USD | 1977.705% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 4965.57% |
| Quantum-Si incorporated | -95.96 Million USD | 470.735% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 398.883% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 2540.408% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -168.841% |
| SciSparc Ltd. | -5.12 Million USD | 7045.666% |
| Vericel Corporation | -3.18 Million USD | 11280.295% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 295937.976% |
| Minerva Neurosciences, Inc. | -30 Million USD | 1285.645% |
| Generation Bio Co. | -126.61 Million USD | 380.982% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 588.067% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 531.524% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 235.713% |
| Invivyd, Inc. | -198.64 Million USD | 279.094% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 204.031% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 4195.482% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -1459.927% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 3702.967% |
| 2seventy bio, Inc. | -217.57 Million USD | 263.514% |
| ADMA Biologics, Inc. | -28.23 Million USD | 1359.807% |
| Clene Inc. | -49.5 Million USD | 818.643% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 1696.215% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 819.661% |
| GeoVax Labs, Inc. | -25.96 Million USD | 1470.048% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 208.441% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 1193.194% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -1465.832% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 460.108% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 575.904% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 321.235% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 157.841% |
| Evaxion Biotech A/S | -22.12 Million USD | 1707.941% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 540.642% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 277.818% |
| Trevena, Inc. | -40.28 Million USD | 983.013% |
| Surrozen, Inc. | -43.04 Million USD | 926.535% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 614.591% |
| Cingulate Inc. | -23.53 Million USD | 1611.612% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 5246.947% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 992.516% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 4713.826% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 494.365% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 680.487% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 697.881% |
| Clearmind Medicine Inc. | -11.95 Million USD | 3075.793% |
| Kronos Bio, Inc. | -112.67 Million USD | 415.743% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 614.122% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 14027100.706% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 514.177% |
| Statera Biopharma, Inc. | -174.4 Million USD | 303.98% |
| ImmunityBio, Inc. | -583.19 Million USD | 161.001% |
| Korro Bio, Inc. | -81.17 Million USD | 538.276% |
| Kineta, Inc. | -14.09 Million USD | 2623.278% |
| BioVie Inc. | -32.12 Million USD | 1207.569% |
| Codexis, Inc. | -76.24 Million USD | 566.628% |
| Celularity Inc. | -196.29 Million USD | 281.236% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 265.832% |
| Celcuity Inc. | -63.77 Million USD | 657.795% |
| Virax Biolabs Group Limited | -6.73 Million USD | 5383.36% |
| Cibus, Inc. | -267.62 Million USD | 232.93% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 982.203% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 1093.429% |
| IN8bio, Inc. | -30 Million USD | 1285.58% |
| Kodiak Sciences Inc. | -260.49 Million USD | 236.572% |
| Annexon, Inc. | -134.23 Million USD | 365.022% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 403.638% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 681.036% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 1227.812% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 197.125% |
| Eyenovia, Inc. | -27.26 Million USD | 1404.999% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -1547.71% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 66596.636% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 565.626% |
| Arcellx, Inc. | -70.69 Million USD | 603.264% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 958.466% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 365.855% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 1284.396% |
| Moolec Science SA | -51.78 Million USD | 786.937% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 779.302% |
| Geron Corporation | -184.12 Million USD | 293.213% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 947.565% |
| Royalty Pharma plc | 1.13 Billion USD | 68.651% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 361.671% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 4100.955% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 1774.684% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 307.233% |
| Humacyte, Inc. | -110.77 Million USD | 421.15% |
| Structure Therapeutics Inc. | -89.62 Million USD | 496.962% |
| 89bio, Inc. | -142.18 Million USD | 350.2% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 615.889% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 3528.322% |
| Genelux Corporation | -28.29 Million USD | 1357.225% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 1324.005% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 300.858% |
| Notable Labs, Ltd. | -11.26 Million USD | 3258.354% |
| Liquidia Corporation | -78.5 Million USD | 553.182% |
| Mustang Bio, Inc. | -51.6 Million USD | 789.425% |
| Immunovant, Inc. | -259.33 Million USD | 237.18% |
| Quantum-Si incorporated | -95.96 Million USD | 470.735% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 588.349% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 1935.597% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 470.619% |
| Acasti Pharma Inc. | -12.85 Million USD | 2867.891% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 1684.109% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 2328.822% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 295.05% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 8370.501% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 2952.903% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 1306.324% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 1012.478% |
| PepGen Inc. | -78.62 Million USD | 552.467% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 1295.059% |
| United Therapeutics Corporation | 984.8 Million USD | 63.875% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 1698.19% |
| Solid Biosciences Inc. | -96.01 Million USD | 470.522% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 7524.805% |
| Immuneering Corporation | -53.47 Million USD | 765.319% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 7093.414% |
| Silo Pharma, Inc. | -3.7 Million USD | 9713.279% |
| Belite Bio, Inc | -31.63 Million USD | 1224.674% |
| XOMA Corporation | -40.83 Million USD | 971.291% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 754.386% |
| Bionomics Limited | -15.49 Billion USD | 102.296% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 523.596% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 1320.143% |
| uniQure N.V. | -308.47 Million USD | 215.327% |
| Cassava Sciences, Inc. | -97.21 Million USD | 465.941% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 4965.57% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 388.226% |
| Forte Biosciences, Inc. | -31.47 Million USD | 1230.248% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 4437.599% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 1323.878% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 66596.636% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 1456.195% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 2258.065% |
| Altimmune, Inc. | -88.44 Million USD | 502.226% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 334.693% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 1320.143% |
| Compugen Ltd. | -18.75 Million USD | 1996.966% |
| Peak Bio, Inc. | -1259.26 USD | 28251374.558% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 872.562% |
| Benitec Biopharma Inc. | -21.75 Million USD | 1735.589% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 205.008% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 528.861% |
| Zura Bio Limited | -60.36 Million USD | 689.392% |
| PolyPid Ltd. | -23.86 Million USD | 1590.706% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 2361.359% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 528.861% |
| Instil Bio, Inc. | -156.08 Million USD | 327.922% |
| argenx SE | -295.05 Million USD | 220.574% |
| Immunome, Inc. | -106.8 Million USD | 433.087% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 937.193% |
| Verona Pharma plc | -54.36 Million USD | 754.338% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 456.053% |
| Shattuck Labs, Inc. | -87.29 Million USD | 507.52% |
| CervoMed Inc. | -2.17 Million USD | 16480.194% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 385.402% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 2771.651% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 916.799% |
| Moolec Science SA | -51.78 Million USD | 786.937% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 2057482.344% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 363.295% |
| AnaptysBio, Inc. | -163.61 Million USD | 317.43% |
| Design Therapeutics, Inc. | -66.86 Million USD | 632.077% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 536.973% |
| NeurAxis, Inc. | -14.62 Million USD | 2532.247% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 1039.119% |
| Lumos Pharma, Inc. | -34.03 Million USD | 1145.299% |
| Achilles Therapeutics plc | -69.66 Million USD | 610.668% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 456.053% |
| 180 Life Sciences Corp. | -19.93 Million USD | 1884.575% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -11723.923% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 14027100.706% |
| Nutriband Inc. | -5.48 Million USD | 6585.627% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 453.295% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 831.905% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 561.477% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 1147.268% |
| MoonLake Immunotherapeutics | -36 Million USD | 1088.015% |
| Palisade Bio, Inc. | -12.3 Million USD | 2992.333% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 944.547% |
| Beam Therapeutics Inc. | -132.52 Million USD | 368.441% |
| Neurogene Inc. | -36.31 Million USD | 1079.588% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 317.702% |
| AEON Biopharma, Inc. | -52.55 Million USD | 776.91% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 462.474% |
| Sesen Bio, Inc. | -19.88 Million USD | 1889.162% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 596.978% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 2942.896% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 180.119% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 418.876% |
| Athira Pharma, Inc. | -117.67 Million USD | 402.329% |
| Vaccinex, Inc. | -20.25 Million USD | 1856.738% |
| HCW Biologics Inc. | -24.99 Million USD | 1523.354% |
| XOMA Corporation | -40.83 Million USD | 971.291% |
| Nektar Therapeutics | -276.05 Million USD | 228.871% |
| Arvinas, Inc. | -367.3 Million USD | 196.857% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 528517.378% |
| Merus N.V. | -154.93 Million USD | 329.611% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 465.149% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 1233.526% |
| Rezolute, Inc. | -68.45 Million USD | 619.664% |
| Clene Inc. | -49.5 Million USD | 818.643% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 2406.595% |
| BeyondSpring Inc. | -21.02 Million USD | 1791.986% |
| Synlogic, Inc. | -57.28 Million USD | 721.062% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 3089.303% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 3386.135% |
| Peak Bio, Inc. | -1259.26 USD | 28251374.558% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 1052.037% |
| Krystal Biotech, Inc. | 10.93 Million USD | -3154.272% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 348.609% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 209.429% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 7802.093% |
| MannKind Corporation | -11.93 Million USD | 3080.039% |
| Ikena Oncology, Inc. | -68.16 Million USD | 621.898% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 1792.872% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 482.81% |
| Gossamer Bio, Inc. | -179.81 Million USD | 297.844% |
| CohBar, Inc. | -11.96 Million USD | 3074.03% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 1479.545% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 1279.957% |
| Legend Biotech Corporation | -518.25 Million USD | 168.645% |
| Mural Oncology plc | -207.44 Million USD | 271.493% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 386.635% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 2045.119% |
| Disc Medicine, Inc. | -76.42 Million USD | 565.474% |
| Champions Oncology, Inc. | -7.27 Million USD | 4989.458% |
| REGENXBIO Inc. | -263.49 Million USD | 235.015% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 3452.064% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 848.883% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 1036.609% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 455.178% |
| Vaxart, Inc. | -82.46 Million USD | 531.404% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -106489.706% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 1047.611% |
| Cellectis S.A. | -101.05 Million USD | 452.029% |
| Longeveron Inc. | -21.41 Million USD | 1761.407% |
| Repare Therapeutics Inc. | -93.79 Million USD | 479.288% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 166.375% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 599.876% |
| Revolution Medicines, Inc. | -436.36 Million USD | 181.527% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 5514.047% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 1254.156% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 613.114% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 649.584% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 3726.103% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 90.171% |
| Denali Therapeutics Inc. | -145.22 Million USD | 344.971% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 295937.976% |
| Veru Inc. | -93.15 Million USD | 481.907% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 1416.205% |
| Cingulate Inc. | -23.53 Million USD | 1611.612% |
| Passage Bio, Inc. | -102.06 Million USD | 448.569% |
| Context Therapeutics Inc. | -23.96 Million USD | 1584.535% |
| Exicure, Inc. | -16.91 Million USD | 2203.329% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 288.314% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 1042.053% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 5567.024% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 292.636% |
| Nuvalent, Inc. | -126.21 Million USD | 381.857% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 3483.118% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 509.486% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 1264.736% |
| OmniAb, Inc. | -50.61 Million USD | 802.813% |
| Anew Medical, Inc. | 1.34 Million USD | -26328.229% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 2317.245% |
| Lipocine Inc. | -16.35 Million USD | 2275.607% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 635.827% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 658.707% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 943.15% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 841.67% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 1893.944% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 165.7% |
| Ocugen, Inc. | -63.07 Million USD | 663.995% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 471.618% |
| Q32 Bio Inc. | -112.96 Million USD | 414.938% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 2169.317% |
| Alumis Inc. Common Stock | -154.99 Million USD | 329.531% |
| Equillium, Inc. | -13.33 Million USD | 2767.844% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 689.333% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 4553.734% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 1987.182% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 702.141% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 410.632% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 2035.781% |
| Dominari Holdings Inc. | -22.88 Million USD | 1654.746% |
| Edesa Biotech, Inc. | -8.37 Million USD | 4348.142% |
| vTv Therapeutics Inc. | -20.25 Million USD | 1856.825% |
| Bio-Techne Corporation | 168.1 Million USD | -111.628% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 201.042% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -176.095% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 392.006% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 1037.708% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 415.83% |
| Nkarta, Inc. | -117.5 Million USD | 402.769% |
| BioCardia, Inc. | -11.57 Million USD | 3174.557% |
| Iterum Therapeutics plc | -38.37 Million USD | 1027.151% |